Citation: Ragini C Bhake, Stafford L Lightman. A Simple Complex Case: Restoration of Circadian Cortisol Activity[J]. AIMS Medical Science, 2015, 2(3): 182-185. doi: 10.3934/medsci.2015.3.182
[1] | Milner MR, Semmes L, Silverman A, et al. (1990) Familial Cushing's Syndrome (“Carney Complex”). New Eng J Med 322 (20): 1469-1470 |
[2] | Carney JA, Young Jr, WF (1992) Primary pigmented nodular adrenocortical disease and its associated conditions. The Endocrinologist 2(1): 6-21 |
[3] | Stratakis CA (1998) Carney Complex: Diagnosis and management of the complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas. Am J Med Genet 80: 183-185 doi: 10.1002/(SICI)1096-8628(19981102)80:2<183::AID-AJMG19>3.0.CO;2-I |
[4] | Stratakis CA, Kirschner LS, Carney JA (2001) Clinical and molecular features of the Carney complex: Diagnostic criteria and recommendations for patient evaluation. J Clin Endocr Metab 86(9): 4041-4046 |
[5] | Anselmo J, Medeiros S, Carneiro V, et al. (2012) A large family with Carney complex caused byS147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer. J Clin Endocr Metab 97: 351-359 doi: 10.1210/jc.2011-2244 |
[6] | Bertherat J (2006) Carney complex. Orphanet J Rare Dis 1:21 doi:10.1186/1750-1172-1-21 doi: 10.1186/1750-1172-1-21 |
[7] | Stratakis CA, Sarlis N, Kirschner LS, et al. (1999) Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Int Med 131: 585-591 |
[8] | Sarlis NJ, Chrousos GP, Doppman JL, et al. (1997) Primary pigmented nodular adrenocortical disease: Reevaluation of a patient with Carney complex 27 years after unilateral adrenalectomy. J Clin Endocr Metab 82: 1274-1278 doi: 10.1210/jcem.82.4.3857 |
[9] | Schteingart DE (2009) Drugs in the medical treatment of Cushing's syndrome. Expert Opinion Emer Drug 14(4): 661-671 |
[10] | Porpiglia F, Fiori C, Bovio S, et al. (2004) Bilateral adrenalectomy for Cushing's syndrome: A comparison between laparoscopy and open surgery. J Endoc Invest 27: 654-658 doi: 10.1007/BF03347498 |
[11] | Fleseriu M, Biller BMK, Findling JW, et al. (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endoc Metab 97 (6): 2039-2049 |
[12] | Castinetti F, Fassnacht M, Johanssen S, et al. (2009) Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endoc 160: 1003-1010 |
[13] | Stavreva DA, Wiench M, John S, et al. (2009) Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol 11(9): 1093-1102 |